Levosimendan Accord

Levosimendan, the active ingredient in Levosimendan Accord, is a calcium sensitizer presented as an intravenous formulation for intravenous use. It enhances myocardial contractility and reduces cardiac preload and afterload, providing symptomatic relief in acute decompensated heart failure patients with severe left ventricular dysfunction.

GNH USA supplies Levosimendan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, sourcing the product from EU‑authorized manufacturers. Our distribution network ensures timely delivery and regulatory compliance across multiple regions.

Levosimendan is used in the management of acute heart failure, acting as a calcium sensitizer to improve cardiac performance.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. Severe left ventricular failure: increases contractility in patients with markedly reduced ejection fraction. Low cardiac output states: helps stabilize hemodynamics while definitive therapy is arranged.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Headache - Hypotension - Nausea - Dizziness - Flushing - Palpitations

Serious or Rare Side Effects: - Severe hypotension leading to syncope - Ventricular arrhythmias - Myocardial ischemia - Allergic skin reactions - Significant electrolyte disturbances (e.g., hypokalemia) - Elevated liver enzymes

Levosimendan requires careful monitoring and specific safety measures.

Monitor blood pressure: check regularly for hypotensive episodes. Assess cardiac rhythm: watch for new or worsening arrhythmias. Evaluate renal function: adjust use if renal impairment is present. Review electrolyte status: especially potassium and magnesium levels. Use with caution in recent myocardial infarction: risk of ischemia may be increased. Store at controlled room temperature: keep in original container, protect from light and moisture.

Levosimendan can interact with other cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid): - Concomitant vasodilators (e.g., nitroglycerin) may cause profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole) can increase drug exposure. - Other calcium sensitizers may produce additive inotropic effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers may blunt desired hemodynamic response. - Loop diuretics can exacerbate electrolyte imbalances. - ACE inhibitors may increase the risk of hypotension when combined.